Prostate Cancer Prevention Trial identifies men mostly likely to undergo challenging study procedure

August 13, 2014

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study published in Cancer Epidemiology, Biomarkers and Prevention – a journal of the American Association for Cancer Research.

The Prostate Cancer Prevention Trial was a randomized, double-blind, placebo-controlled trial which tested the efficacy of finasteride, a drug used for . This study was conducted by SWOG – a cooperative group that designs and conducts multidisciplinary .

Researchers at The University of Texas MD Anderson Cancer Center and the Fred Hutchinson Cancer Research Center used a systematic model to identify factors associated with adhering to the end-of-study (EOS) biopsy requirement of the trial. The EOS biopsy, an invasive procedure that examines the cells or tissues of the prostate gland to determine if cancer is evident, is an important part of the study.

"Our study is unique because it evaluated factors prospectively associated with an invasive biopsy for a trial, not a cancer treatment trial," said Ellen R. Gritz, Ph.D., chair of Behavioral Science at MD Anderson, and lead author on the study.

The prevention trial was coordinated by SWOG at 219 sites involving more than 18,000 men. Participants were randomized into one of two groups; those administered finasteride and those given a placebo. Participants received educational materials about the study and biopsy procedures and were asked to attend regularly scheduled appointments throughout the trial.

Funded by the National Cancer Institute, scientists analyzed healthy men over a seven-year period to identify which factors at the six-year study mark were associated with the willingness of the participant to undergo a biopsy. The factors examined included psychosocial outcomes, participant health status, participant adherence, and characteristics of the clinical sites at which the study was conducted.

"The biopsy provided the biological specimens that could be tested to see if a man's prostate cells were cancer-free after seven years on the trial," said Carol Moinpour, Ph.D., of the Fred Hutchinson Cancer Research Center. "That is, the biopsy provided definitive information about which men had seven years after the study started."

Researchers were able to assess factors associated with adherence for more than 13,000 men from the trial, and analyzed factors based on whether or not study had been prompted for a clinical biopsy by year six of the study.

Researchers found participants were more likely to adhere to the EOS biopsy if one year prior to the biopsy they were adherent to the study drug, kept appointments and underwent required tests and were in good health. Participants who had an EOS biopsy were more likely to be adherent to the study drug at year six – 84 percent. Among participants who were not biopsied, only 47 percent were adherent to the study drug. Results also showed that 98 percent of men who had an EOS biopsy had the DRE (digital rectal exam) or PSA test done at year six, compared to 75 percent of men who did not have the EOS .

"We also found that participants were more likely to adhere to biopsies if the study site that recruited the participant enrolled more than 200 participants and/or had resources for conducting activities to encourage continued participation in the trial," said Gritz.

Researchers said monitoring adherence behaviors in clinical trial participants can help identify participants at risk for noncompliance to a study requirement, and help create a model for adherence intervention strategies in future .

"If we are able to determine which factors are associated with good adherence to study regimens evaluating prevention agents, we may be able to improve the conduct of such large trials by targeting interventions to boost adherence," said Gritz.

Explore further: New accurate epigenetic test could eliminate unnecessary repeat biopsies for prostate cancer

Related Stories

New accurate epigenetic test could eliminate unnecessary repeat biopsies for prostate cancer

July 21, 2014
More than one million prostate biopsies are performed each year in the U.S. alone, including many repeat biopsies for fear of cancer missed. Therefore there is a need to develop diagnostic tests that will help avoid unnecessary ...

Version 2.0 of Prostate Cancer Risk Calculator now online, complete with emojis

August 4, 2014
A calculator to help men and their doctors assess their risk of prostate cancer, developed at the UT Health Science Center, has had a major upgrade to enhance how men and their physicians better understand a man's risk of ...

Physical symptoms from prostate biopsy can cause anxiety

October 23, 2013
(HealthDay)—Problematic symptoms of prostate biopsy can lead to increased anxiety in men, even when the biopsy results are negative for cancer, according to research published online Oct. 21 in the Journal of Clinical Oncology.

Study shows image fusion-guided biopsy improves accuracy of prostate cancer diagnosis

May 21, 2014
A recent study by investigators from LIJ Medical Center demonstrated that using magnetic resonance imaging (MRI) in men with an elevated prostate specific antigen (PSA) resulted in a prostate cancer detection rate that was ...

Chronic inflammation linked to 'high-grade' prostate cancer

April 18, 2014
Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers ...

Gene therapy combined with IMRT found to reduce recurrence for select prostate cancer patients

June 2, 2014
Combining oncolytic adenovirus-mediated cytotoxic gene therapy (OAMCGT) with intensity modulated radiation therapy (IMRT) reduces the risk of having a positive prostate biopsy two years after treatment in intermediate-risk ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.